Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
Aprea Therapeutics, Inc. | Director | Common Stock | 1.84K | $13.4K | $7.29 | Jun 20, 2024 | Direct |
Akari Therapeutics Plc | Director | Ordinary Shares, par value $0.0001 per share | 20M | Jan 1, 2024 | Direct | ||
Akari Therapeutics Plc | Director | Stock Option (Right to Buy) | 5M | Jun 28, 2024 | Direct | ||
Aprea Therapeutics, Inc. | Director | Stock Options (Right to Buy) | 4.19K | Jun 20, 2024 | Direct |
Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
---|---|---|---|---|---|---|---|
AKTX | Akari Therapeutics Plc | Jun 28, 2024 | 1 | $0 | 4 | Jul 2, 2024 | Director |
APRE | Aprea Therapeutics, Inc. | Jun 20, 2024 | 2 | $0 | 4 | Jun 21, 2024 | Director |
AKTX | Akari Therapeutics Plc | Jan 1, 2024 | 0 | $0 | 3 | Jan 2, 2024 | Director |
APRE | Aprea Therapeutics, Inc. | Aug 23, 2023 | 2 | $0 | 4 | Aug 24, 2023 | Director |
APRE | Aprea Therapeutics, Inc. | Jul 28, 2022 | 2 | $0 | 4 | Aug 1, 2022 | Director |
APRE | Aprea Therapeutics, Inc. | May 16, 2022 | 0 | $0 | 3 | May 26, 2022 | Director |